Email this article Osteoprotegerin and bone mineral density in patients with chronic obstructive pulmonary disease
- Authors: Kochetkova EA1, Nevzorova VA2, Maistrovskaya Y.V2, Massard G3
-
Affiliations:
- University Hospital, Strasbourg, FranceVladivostok State Medical University, Vladivostok
- Vladivostok State Medical University, Vladivostok
- University Hospital, Strasbourg, France
- Issue: Vol 82, No 8 (2010)
- Pages: 10-14
- Section: Editorial
- URL: https://ter-arkhiv.ru/0040-3660/article/view/30606
- ID: 30606
Cite item
Full Text
Abstract
Aim: to study a relationship between the serum level of osteoprotegerin (OPG), the markers of bone metabolism, tumor necrosis factor-α (TNF-α), and bone mineral density (BMD) in patients with chronic obstructive pulmonary disease (COPD).
Subjects and methods. Fifty-five patients aged 44 to 58 years who had COPD were examined. BMD in the lumbar spine (LII-LIV) and left femoral neck (FN) was estimated by dual-energy X-ray absorptiometry (DXA) on Lunar Prodigy Densitometer (USA). The serum levels of OPG, BCrossLaps (BCL), and TNF-α were measured. A control group comprised 25 healthy non-smoking gender- and age-matched volunteers.
Results. Osteopenic syndrome (T-test < -1SD) was recorded in 43 (78%) of the 55 examined patients with COPD. In 29 (52%) of them, T-test was lower in two zones towards osteoporosis in 14 (25%) towards osteopenia. In patients with COPD, TNF-α concentrations were significantly higher than that in the control group. At the same time, TNF-α levels correlated positively with the bone resorption marker BCL (r = 0.52; p = 0.042) and negatively with OPG (r = 0.56; p = 0.003). A direct correlation was established between serum OPG concentrations and BMD in both LII-LIV and FN (r = 0.56; p < 0.01 and r = 0.47; p < 0.05, respectively)
Conclusion. The patients with COPD were found to have lower BMD, elevated TNF-α concentrations, an increased bone resorption marker, and lower serum OPG levels. The associations between the levels of OPG, TNF-α, and BMD suggest that these markers are implicated in the pathogenesis of osteopenic syndrome in COPD.
Subjects and methods. Fifty-five patients aged 44 to 58 years who had COPD were examined. BMD in the lumbar spine (LII-LIV) and left femoral neck (FN) was estimated by dual-energy X-ray absorptiometry (DXA) on Lunar Prodigy Densitometer (USA). The serum levels of OPG, BCrossLaps (BCL), and TNF-α were measured. A control group comprised 25 healthy non-smoking gender- and age-matched volunteers.
Results. Osteopenic syndrome (T-test < -1SD) was recorded in 43 (78%) of the 55 examined patients with COPD. In 29 (52%) of them, T-test was lower in two zones towards osteoporosis in 14 (25%) towards osteopenia. In patients with COPD, TNF-α concentrations were significantly higher than that in the control group. At the same time, TNF-α levels correlated positively with the bone resorption marker BCL (r = 0.52; p = 0.042) and negatively with OPG (r = 0.56; p = 0.003). A direct correlation was established between serum OPG concentrations and BMD in both LII-LIV and FN (r = 0.56; p < 0.01 and r = 0.47; p < 0.05, respectively)
Conclusion. The patients with COPD were found to have lower BMD, elevated TNF-α concentrations, an increased bone resorption marker, and lower serum OPG levels. The associations between the levels of OPG, TNF-α, and BMD suggest that these markers are implicated in the pathogenesis of osteopenic syndrome in COPD.
About the authors
E A Kochetkova
University Hospital, Strasbourg, FranceVladivostok State Medical University, Vladivostok
Email: zkochetkova@mail.ru
University Hospital, Strasbourg, FranceVladivostok State Medical University, Vladivostok
V A Nevzorova
Vladivostok State Medical University, Vladivostok
Email: nevzorova@inbox.ru
Vladivostok State Medical University, Vladivostok
Yu V Maistrovskaya
Vladivostok State Medical University, Vladivostok
Email: maistr30175@mail.ru
Vladivostok State Medical University, Vladivostok
G Massard
University Hospital, Strasbourg, France
Email: gilbert.massard@chru-strasbourg.fr
University Hospital, Strasbourg, France
References
- Biskobing D. M. COPD and osteoporosis. Chest 2002; 121 (2): 609-620.
- Hofbauer L. C., Khosla S., Dunstan C. R. et al. The role of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J. Bone Miner. Res. 2000; 15: 2-12.
- Dougall W. C., Chaisson M. The RANKL/RANK/OPG triad in cancer-induced bone diseases. Cancer Metastas. Rev. 2006; 25: 541-549.
- Regmi A., Fuson T., Yang X. et al. Suranin interacts with RANK and inhibits RANKL-induced osteoclast differentiation. Bone 2005; 36: 284-297.
- Sattler A. M., Schoppet M., Schaefer J. R., Hofbauer L. C. Novel aspects on RANK and osteoprotegerin in osteoporosis and vascular disease. Calcif. Tissue Int. 2004; 74: 103-106.
- Giuliani N., Pedrazzoni M., Negri G. et al. Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo. Bone 1998; 22: 455-461.
- Eghbali-Fatourechi G., Khosla S., Sanyal A. et al. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J. Clin. Invest. 2003; 111: 1221- 1223.
- Bucay N., Sarosi I., Dunstan C. R. et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998; 12: 1260-1268.
- Dobnig H., Hofbauer L. C., Viereck V. et al. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. Osteoporos. Int. 2006; 17: 693-703.
- Mezquita-Raya P., Higuera M., Garcia D. F. et al. The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women. Osteoporos. Int. 2005; 16: 1368-1374.
- Khosla S., Arrighi H. M., Melton III L. J. et al. Correlates of osteoprotegerin levels in women and men. Osteoporos. Int. 2002; 13: 394-399.
- Yano K., Tsuda E., Washida N. et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J. Bone Miner. Res. 1999; 14: 518-527.
- Szalay F., Hegedus D., Lakatos P. L. et al. High serum osteoprotegerin and low RANKL in primary biliary cirrhosis. J. Hepatol. 2003; 38: 395-400.
- Shoppet M., Sattler A. M., Herzum M. et al. Increased osteoprotegerin serum levels in men with coronary artery disease. J. Clin. Endocrinol. 2003; 88: 1024-1028.
- Кочеткова Е. А., Волкова М. В., Гельцер Б. И. Цитокиновый статус у больных хронической обструктивной болезнью легких и его взаимосвязь с функциональным состоянием костной ткани. Тер. арх. 2004; 3: 18-23.
- Rogers A., Saleh G., Hannon R. A. et al. Circulating estradiol and osteoprotegerin as determinant of bone turnover and bone density in postmenopausal women. J. Clin. Endocrinol. 2002; 87: 4470-4475.
- Monegal A., Navasa M., Peris P. et al. Serum osteoprotegerin and its ligand in cirrhotic patients referred for osteoporotic liver transplantation: relationship with metabolic bone disease. Liver Int. 2007; 5: 492-497.
- Warren S., Browner W. S., Lui L. Y., Steven R. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J. Clin. Endocrinol. 2001; 86: 631-637.
- Pennisi P., Signorelli S. S., Ricobene S. et al. Low bone density and abnormal in patients with atherosclerosis of peripheral vessels. Osteoporos. Int. 2004; 15: 389-395.
- Baud'huin M., Lamoureux F., Duplomb L. et al. RANKL, RANK, osteoprotegerine: key partners of osteoimmunology and vascular diseases. Cell Mol. Life Sci. 2007; 64: 2334- 2350.
- Incalzi R. A., Caradonna P., Ranieri P. et al. Correlates of osteoporosis in chronic obstructive pulmonary disease. Respir. Med. 2000; 94: 1079-1084.
- Bolton C. E., Ionescu A. A., Shiels K. M. et al. Associated loss fat-free mass and bone mineral density in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2004; 170 (12): 1286-1293.
- Serelis J., Kontogianni M. D., Katsiougiannis S. et al. Effect of anti-TNF treatment on body composition and serum adiponectin level of women with rheumatoid arthritis. Clin. Rheumatol. 2008; 27: 795-797.
- Olesen P., Ledet T., Rasmussen L. M. Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-α. Diabetologia 2005; 48: 561-568.
Supplementary files
